IDH2 and central nervous system cancer: To refine the diagnostic accuracy, we use Sanger sequencing, for example to detect rarer mutations in the IDH1, or IDH2 genes [26], histones [16], or to detect mutations in the TERT promoter either to support glioma diagnostics in the context of other mutations [10] or to prognosticate meningioma recurrence risk [33].